Drug intelligence / Profile preview

buparlisib

Development stage: Phase 3
Lead developer: Adlai Nortye
Modality: Small Molecules
Administration: Oral

Overview

Buparlisib is an investigational, orally available small molecule that acts as a pan-class I phosphoinositide 3-kinase (PI3K) inhibitor. It was developed by Novartis and is currently being further developed by Adlai Nortye. Buparlisib has been studied for its potential in treating various cancers, including breast cancer and head and neck squamous cell carcinoma (HNSCC).

Other names: BKM-120BKM120BKM 120NVP-BKM120NVP-BKM-120NVP-BKM 120BKM-120NXBKM120NXBKM 120NXBuparlisibum

Targets

PIK3CG (Phosphatidylinositol 4,5-bisphosphate 3-kinase gamma)PIK3CA (Phosphoinositide 3-kinase alpha)PIK3CB (Phosphatidylinositol 3-kinase beta subunit)TUBB (Tubulin (alpha and beta subunits))PIK3CD (Phosphatidylinositol 3-kinase delta)

Beyond the preview

Go deeper on buparlisib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on buparlisib.

Explore the full profile